Please login to the form below

Not currently logged in
Email:
Password:

S-A signs ophthalmology deal

Sanofi-aventis has signed a co-operation agreement with one of the main eye disease research centres in Europe

The ophthalmology division of sanofi-aventis (S-A), Fovea Pharmaceuticals, has signed a co-operation agreement with the Institut de la Vision (page is in French), one of the main eye disease research centres in Europe, for research in the diagnosis, prevention and treatment of ocular diseases.

The agreement aims to set up a partnership between S-A and the Institute on the model of translational R&D and to strengthen the company's collaboration with the organisations that make up the Institute, including the Pierre and Marie Curie University, the French National Institute of Health and Medical Research and the French National Center for Scientific Research.

Under the terms of the three-year agreement, S-A will be given priority access to the technological platforms of the Institute to conduct research activities and will support research and collaboration projects in particular in the area of regeneration of the optical nerve, vascular biology, inflammation and gene therapy in various eye tissues. S-A will be granted exclusive and worldwide rights to the results of the collaboration. In the case of commercialisation, it would pay royalties to members of the Institute.

Christopher A Viehbacher, CEO of S-A, said: "This collaboration will encourage the sharing of technical expertise and know-how with the objective to deliver innovative therapies for people with visual impairment and supports our ambition to build a global offer in ophthalmology for patients."

24th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....